Abstract 1834P
Background
The first conversational AI Cancer mentor app was recently launched by Belong.life, a global oncology social network for cancer patients (pts) and caregivers. The app objectives are to provide uninterrupted support and guidance with empathetic, relevant information in cancer management. Belong’s unique and large datasets of pts to physicians and pts to pts interactions provide the basis for the AI platform, adding information from current guidelines, supplying solid up to date data with wide understanding of pts diverse cancer journeys.
Methods
Belong members enquiries, replied by the AI Cancer mentor were validated by 9 oncology experts in solid and haematological cancers, affiliated to various medical centres. 578 member enquiries coupled with the AI Cancer mentor replies, were randomly chosen and distributed according to cancer groups: Breast, Gastrointestinal, Pancreatic, Genitourinary, Musculoskeletal, Haematology and Radiation therapy. The oncologists assessed the AI mentor accuracy of recommendations by relevance and helpfulness, aligning them to evidence-based medicine and current international guidelines.
Results
527/578 (91.18%) AI Cancer mentor replies received a positive validation for their suitable and relevant recommendations. Conversely, 46/578 (7.96%) received a negative validation, while only 5/578 (0.86%) graded as not helpful. Minor variations were noticed in the cancer groups, with positive validations as follows: Genitourinary 100%, Breast 95.7%, Pancreatic 92%, Musculoskeletal 91.2%, Radiation therapy 88%, Gastrointestinal 86.4%, Haematological cancers 84%.
Conclusions
The reported accuracy (91.18%) on 578 pts enquiries and AI Cancer mentor replies, evaluated by a multi-disciplinary, multi-institutional oncologist group, are very promising, indicating that the Belong’s AI cancer mentor provides valuable and reliable recommendations. The findings offered insights into the AI mentor’s performance across a wide group of cancers. Based on this report, the addition of an AI mentor in cancer care, provides helpful, relevant guidance on pts diverse cancer journeys, while supporting oncologists in their pts management.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Haikin, D.A. Vorobiof: Financial Interests, Personal, Full or part-time Employment: Belong.life. All other authors have declared no conflicts of interest.
Resources from the same session
1717TiP - CARE1 pragmatic clinical trial: First line randomised study platform to optimize treatment in patients with metastatic renal cell carcinoma
Presenter: Laurence Albiges
Session: Poster session 12
1822P - Incidence of cachexia and health resource use (HRU) in patients with breast, colorectal, lung, pancreatic, and prostate cancers
Presenter: Imran Ali
Session: Poster session 12
1823P - Significance of skeletal muscle measurement in cancer-associated cachexia screening
Presenter: Lynn Gottmann
Session: Poster session 12
1824P - Sarcopenia in advanced non-small cell lung cancer (NSCLC): Clinical impact and its biological correlates
Presenter: Filippo Dall'Olio
Session: Poster session 12
1826P - Risk factors and incidence of osteoporosis in patients with breast cancer according to gender
Presenter: Chang Ik Yoon
Session: Poster session 12
1827P - Bone health and body composition in prostate cancer: An italian consensus about prevention and management strategies
Presenter: Maria Concetta Cursano
Session: Poster session 12
1828P - A cross-sectional study investigating the current diagnostic & therapeutical approaches to bone metastases (BoM) in patients (pts) with non-small cell lung cancer (NSCLC)
Presenter: Sara Pilotto
Session: Poster session 12
1829P - Nutritional status assessment for patients with common cancer in a cancer hospital of southwest China
Presenter: Huiqing Yu
Session: Poster session 12
Resources:
Abstract
1830P - Comprehensive prognostic effects of inflammatory and nutritional markers to predict survival in women with breast cancer
Presenter: Susanna Hutajulu
Session: Poster session 12
1831P - Obesity and weight variations before treatment, seem to influence weight loss that happens during first-line metastatic lung adenocarcinoma
Presenter: Anthony Tarabay
Session: Poster session 12